Coria Laboratories announces launch of Acanya Gel

Posted on: Mon, 09 Mar 2009 09:39:00 EDT


Symbols: VRX
Mar 09, 2009 (M2 EQUITYBITES via COMTEX) --
VRX | Quote | Chart | News | PowerRating -- Coria Laboratories,Aa newly expanded dermatology division of Valeant
Pharmaceuticals International (NYSE: VRX), declared on 6 March the
commercial launch of Acanya Gel (clindamycin phosphate 1.2% and benzoyl
peroxide 2.5%), which is indicated for the once-daily treatment of acne
vulgaris in patients aged 12 years and older.
A
Acanya Gel, which has been evaluated in clinical studies enrolling over
3,200 subjects with moderate to severe acne vulgaris, is reportedly the
only fixed combination antibiotic and benzoyl peroxide (BPO) medication
FDA-approved for the once-daily treatment of both non-inflammatory and
inflammatory lesions of acne.
A
Acne vulgaris is a common skin disorder affecting about 85% of people
at some point in their lives. The overproduction of sebum, a normal
oily substance on the skin surface, combined with dead skin cells that
are abnormally shed from the hair follicle, leads to plugging of the
follicle. This allows skin bacteria, Propionibacterium acnes, to
multiply and cause inflammation in the skin in the form of an acne
lesion.

Comments on this story may be sent to admin@m2.com

For full details on Valeant Pharmaceuticals (VRX) VRX. Valeant Pharmaceuticals (VRX) has Short Term PowerRatings at TradingMarkets. Details on Valeant Pharmaceuticals (VRX) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.